REGEN-COV (casirivimab/imdevimab) / Regeneron, Roche 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 
19 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
REGEN-COV (casirivimab/imdevimab) / Regeneron, Roche
2021-005051-37: a cohort study for the evaluation of the use of neutralizing monoclonal SARS-CoV-2 antibodies een cohort studie om neutraliserende monoklonale antilichamen te evalueren.

Ongoing
3/4
1000
Europe
REGEN-COV2, -, Injection/infusion
Amsterdam University Medical Centre, Netherlands Organization for Scientific Research, ZonMw
COVID-19 COVID-19, COVID-19 COVID-19, Diseases [C] - Virus Diseases [C02]
 
 
2021-002612-31: Adaptive, randomized, placebo-controlled trial to evaluate the efficacy of monoclonal antibodies in outpatients with mild or moderate COVID-19 (MANTICO) Studio clinico adattativo, randoMizzato, controllato con placebo, sull’uso di ANTIcorpi monoclonali nei pazienti affetti da forma lieve-moderata di COvid-19 (MANTICO)

Not yet recruiting
3
1260
Europe
Bamlanivimab, CASIRIVIMAB/IMDEVIMAB, ETESEVIMAB, [Bamlanivimab], [CASIRIVIMAB/IMDEVIMAB], [ETESEVIMAB], Concentrate for solution for injection/infusion, .
AZIENDA OSPEDALIERA UNIVERSITARIA INTEGRATA VERONA, AIFA - Italian Medicines Agency
COVID-19 COVID-19, COVID-19 COVID-19, Diseases [C] - Virus Diseases [C02]
 
 
2021-004266-35: A multicenter clinical trial to compare the efficacy and safety of Casirivimab and Imdevimab or Bamlanivimab and Etesevimab or Sotrovimab in high risk COVID-19 hospital admission patients. Uno studio clinico multicentrico per confrontare l'efficacia e la sicurezza degli Anticorpi Monoclonali Casirivimab e Imdevimab o Bamlanivimab ed Etesevimab o Sotrovimab in pazienti domiciliari COVID-19 ad alto rischio di ricovero.

Ongoing
3
552
Europe
Casirivimab/imdevimab, Sotrovimab, Bamlanivimab/Etesevimab, [ronapreve], [VIR-7831], [Bamlanivimab/Etesevimab], Concentrate for solution for injection/infusion, Concentrate and solvent for solution for injection, casirivimab/imdevimab, Sotrovimab, Bamlanivimab/Etesevimab
AZIENDA OSPEDALIERO-UNIVERSITARIA DI MODENA, AIFA - Italian Medicines Agency
Mild to moderate COVID-19 patients at high risk of progression to severe COVID-19 and / or hospitalization pazienti affetti da COVID-19 da lieve a moderato ad alto rischio di progressione a COVID-19 grave e/o ricovero ospedaliero, COVID-19 patients pazienti affetti da COVID-19, Diseases [C] - Virus Diseases [C02]
 
 
RECOVERY, NCT04381936 / 2020-001113-21: Randomised Evaluation of COVID-19 Therapy

Checkmark Efficacy and safety data from RECOVERY trial in COVID-19
Jun 2021 - Jun 2021: Efficacy and safety data from RECOVERY trial in COVID-19
Recruiting
3
70000
Europe, RoW
Lopinavir-Ritonavir, Corticosteroid, Hydroxychloroquine, Azithromycin, Convalescent plasma, Tocilizumab, Immunoglobulin, Synthetic neutralising antibodies, REGEN-COV, casirivimab and imdevimab, Aspirin, Colchicine, Baricitinib, Anakinra, Dimethyl fumarate, High Dose Corticosteroid, Empagliflozin, Sotrovimab, Molnupiravir, Paxlovid, nirmatrelvir/ritonavir, Baloxavir Marboxil, Xofluza, Oseltamivir, Tamiflu, Low-dose corticosteroids: Dexamethasone
University of Oxford, UK Research and Innovation, National Institute for Health Research, United Kingdom, Wellcome, Bill and Melinda Gates Foundation, Department for International Development, United Kingdom, Health Data Research UK, Medical Research Council Population Health Research Unit, NIHR Clinical Trials Unit Support Funding, NIHR Health Protection Research Unit in Emerging and Zoonotic Infections, Flu Lab
Severe Acute Respiratory Syndrome
06/26
06/36
COVIC-19, NCT05271929: Early High-Titre Convalescent Plasma in Clinically Vulnerable Individuals With Mild COVID-19

Terminated
3
120
Europe
Current standard of care and COVID-19 convalescent and vaccinated plasma, Current standard of care
Deutsches Rotes Kreuz DRK-Blutspendedienst Baden-Wurttemberg-Hessen, NHS Blood and Transplant, Erasmus Medical Center
COVID-19
01/24
06/24
2020-003690-21: Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Ambulatory Adult Patients With COVID-19

Not yet recruiting
2/3
1368
Europe
REGN10933, REGN10987, REGN10933, REGN10987, Solution for injection/infusion
Regeneron Pharmaceuticals, Inc., Regeneron Pharmaceuticals, Inc.
Coronavirus disease 2019 (COVID-19), COVID-19, Diseases [C] - Virus Diseases [C02]
 
 
2020-002537-15: Safety, Tolerability, and Efficacy of Anti-Spike SARS-CoV-2 Monoclonal Antibodies for Hospitalized Adult Patients With COVID-19

Not yet recruiting
2/3
2970
Europe
REGN10933, REGN10987, REGN10933, REGN10987, Solution for injection/infusion
Regeneron Pharmaceuticals, Inc., Regeneron Pharmaceuticals, Inc.
Coronavirus disease 2019 (COVID-19), COVID-19, Diseases [C] - Virus Diseases [C02]
 
 
NCT04518410: ACTIV-2: A Study for Outpatients With COVID-19

Hourglass Jul 2022 - Dec 2022 : Data from ACTIV-2 trial for COVID-19
Hourglass May 2022 - Dec 2022 : Data from ACTIV-2 trial for the treatment of COVID-19
Checkmark Safety and efficacy data from ACTIV-2 P2/3 trial for the treatment for COVID-19
Jan 2022 - Jan 2022: Safety and efficacy data from ACTIV-2 P2/3 trial for the treatment for COVID-19
Checkmark Data from ACTIV-2 trial in combination with BRII-198 for COVID-19
More
Completed
2/3
4044
Canada, US, RoW
bamlanivimab 7000mg, LY3819253, BRII-196+BRII-198, AZD7442 (IV), AZD8895 + AZD1061, AZD7442 (IM), SNG001, Camostat, FOY-305, camostat mesilate, camostat mesylate, BMS-986414 + BMS-986413, C135-LS + C144-LS, SAB-185 (3,840 Units/kg), Anti-SARS-CoV-2 Human Immunoglobulin Intravenous (Tc bovine-derived), SAB-185 (10,240 Units/kg), CASIRIVIMAB + IMDEVIMAB, REGN10933 + REGN10987, REGN-COV2, Placebo for Bamlanivimab 7000mg, Placebo for Bamlanivimab 700mg, Placebo for BRII-196+BRII-198, Placebo for SNG001, Placebo for Camostat, Placebo for SAB-185 (low dose), Placebo for BMS-986414 + BMS-986413, Placebo for AZD7442 (IV), Placebo for AZD7442 (IM), Placebo for SAB-185 (high dose), bamlanivimab 700mg
National Institute of Allergy and Infectious Diseases (NIAID), Eli Lilly and Company, Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections, Brii Biosciences Limited, AstraZeneca, Sagent Pharmaceuticals, Synairgen Research Ltd., Bristol-Myers Squibb, SAb Biotherapeutics, Inc.
Coronavirus, Covid19
04/22
06/23
NCT05149300 / 2021-004590-30: COVID-19 Administration of Single-Dose Subcutaneous Anti- Spike(s) SARS-CoV-2 Monoclonal Antibodies Casirivimab and Imdevimab in High-Risk Pediatric Participants Under 12 Years of Age

Recruiting
2a
28
US
casirivimab+imdevimab, REGN10933-10987, REGN-COV2, REGEN-COV™, RONAPREVE™
Regeneron Pharmaceuticals, Regeneron Pharmaceuticals Inc
COVID-19
11/22
11/22
NCT04840459: Use of Monoclonal Antibodies for the Treatment of Mild to Moderate COVID-19 in Non-Hospitalized Setting

Recruiting
2
1000
US
BAMLANIVIMAB, CASIRIVIMAB, IMDEVIMAB
Sohail Rao
Covid19
12/22
01/23
PLATCOV, NCT05041907: Finding Treatments for COVID-19: A Trial of Antiviral Pharmacodynamics in Early Symptomatic COVID-19

Recruiting
2
3800
RoW
Nirmatrelvir/ritonavir (e.g. PAXLOVID™), Nitazoxanide, Molnupiravir and nirmatrelvir/ritonavir (e.g. PAXLOVID™), Hydroxychloroquine, No treatment, Monoclonal antibodies, Fluoxetine, Molnupiravir, Sotrovimab, Ensitrelvir, Favipiravir, Ivermectin, Remdesivir, Atilotrelvir/ritonavir, Metformin, Nirmatrelvir/ritonavir, Nirmatrelvir
University of Oxford
COVID-19
01/27
01/27
NCT04790240: Medical Herbs Inhibit Inflammation Directing T Cells to Kill the COVID-19 Virus (COVID)

Recruiting
1/2
120
US
Inflammation (I), PurInf (I), PurInf (II), PurInf(III), Inflammation (II), PurCo, Inflammation (III), PurPhl, PurClo, Standard of care, Medications
All Natural Medicine Clinic, LLC
Covid19 Virus Infection
12/22
03/23
CasiTocCOVID, NCT06233357: Critically Ill ICU Patients Under Casirivimab- and/or Tocilizumab Application

Completed
N/A
95
Europe
treated without (N), with casirivimab / imdevimab (C) or tocilizumab (T), solely, or in combination of both (C + T), casirivimab / imdevimab, tocilizumab
University of Ulm
COVID-19, Outcome, Fatal, Tocilizumab, Interleukin 6, Critically Ill
04/22
12/23
COVIMAB, NCT05439044: A Real-World Study of Anti-SARS-CoV-2 Monoclonal Antibodies

Recruiting
N/A
4000
Europe
Data collection
Assistance Publique - Hôpitaux de Paris
Immunocompromised Patients
12/22
12/22
NCT04885452: Prevention of COVID-19 Complications in High-risk Subjects Infected by SARS-CoV-2 and Eligible for Treatment Under a Cohort ATU ('Autorisation Temporaire d'Utilisation') OR or Authorisation for Early Access (AAP). A Prospectvie Cohort.

Recruiting
N/A
2000
Europe
biobank
ANRS, Emerging Infectious Diseases
SARS-CoV Infection, Covid19
06/23
06/23
NCT04617535: Compassionate Use of REGN-COV2 for the Treatment of COVID-19

No Longer Available
N/A
NA
REGN10933+REGN10987 combination therapy, REGN-COV2, Casirivimab, Imdevimab, REGEN-COV™, Ronapreve™
Regeneron Pharmaceuticals
COVID-19
 
 
COVID-PR, NCT05013632: COVID-19 International Drug Pregnancy Registry

Recruiting
N/A
2000
US
Antiviral Agents, Veklury (remdesivir), Lagevrio (molnupiravir), Monoclonal antibody, REGEN-COV (casirivimab/imdevimab), Xevudy (sotrovimab)
Pregistry
Covid19
09/27
09/27
CONDIVIDIAMO, NCT05268601: COVID-19 and Disease Progression to the Severe Form: A Study on the Use of Monoclonal Antibodies Against SARS-CoV-2

Recruiting
N/A
1000
Europe
Bamlanivimab, Bamlanivimab and Etesevimab Drug Combination, Casirivimab and Imdevimab Drug Combination, Sotrovimab
University of Milano Bicocca
COVID-19
12/23
05/24
TURN-COVID, NCT05195060: Biobank: The Dutch Cohort Study for the Evaluation of the Use of Neutralizing Monoclonal Antibodies and Other Antiviral Agents Against SARS-CoV-2

Recruiting
N/A
1000
Europe
casirivimab with imdevimab, REGEN-COV, sotrovimab, Xevudy, molnupiravir, Lagevrio
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
COVID-19
06/24
06/24

Download Options